Unknown

Dataset Information

0

Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study.


ABSTRACT:

Background

Well-designed studies with sufficient sample size comparing andexanet alfa vs 4-factor prothrombin complex concentrate (4F-PCC) in routine clinical practice to evaluate clinical outcomes are limited.

Objectives

To compare in-hospital mortality in patients hospitalized with rivaroxaban- or apixaban-related major bleeding who were treated with andexanet alfa or 4F-PCC.

Methods

An observational cohort study (ClinicalTrials.gov identifier: NCT05548777) was conducted using electronic health records between May 2018 and September 2022 from 354 U.S. hospitals. Inclusion criteria were age ≥18 years, inpatient admission with diagnosis code D68.32 (bleeding due to extrinsic anticoagulation), a record of use of the factor Xa inhibitors rivaroxaban or apixaban, andexanet alfa or 4F-PCC treatment during index hospitalization, and a documented discharge disposition. Multivariable logistic regression on in-hospital mortality with andexanet alfa vs 4F-PCC was performed. The robustness of the results was assessed via a supportive propensity score-weighted logistic regression.

Results

The analysis included 4395 patients (andexanet alfa, n = 2122; 4F-PCC, n = 2273). There were 1328 patients with intracranial hemorrhage (ICH), 2567 with gastrointestinal (GI) bleeds, and 500 with critical compartment or other bleed types. In the multivariable analysis, odds of in-hospital mortality were 50% lower for andexanet alfa vs 4F-PCC (odds ratio [OR], 0.50; 95% CI, 0.39-0.65; P < .01) and were consistent for both ICH (OR, 0.55; [0.39-0.76]; P < .01) and GI bleeds (OR, 0.49 [0.29-0.81]; P = .01). Similar results were obtained from the supporting propensity score-weighted logistic regression analyses.

Conclusion

In this large observational study, treatment with andexanet alfa in patients hospitalized with rivaroxaban- or apixaban-related major bleeds was associated with 50% lower odds of in-hospital mortality than 4F-PCC. The magnitude of the risk reduction was similar in ICH and GI bleeds.

SUBMITTER: Dobesh PP 

PROVIDER: S-EPMC10518480 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study.

Dobesh Paul P PP   Fermann Gregory J GJ   Christoph Mary J MJ   Koch Bruce B   Lesén Eva E   Chen Hungta H   Lovelace Belinda B   Dettling Theresa T   Danese Mark M   Ulloa Julie J   Danese Sherry S   Coleman Craig I CI  

Research and practice in thrombosis and haemostasis 20230830 6


<h4>Background</h4>Well-designed studies with sufficient sample size comparing andexanet alfa vs 4-factor prothrombin complex concentrate (4F-PCC) in routine clinical practice to evaluate clinical outcomes are limited.<h4>Objectives</h4>To compare in-hospital mortality in patients hospitalized with rivaroxaban- or apixaban-related major bleeding who were treated with andexanet alfa or 4F-PCC.<h4>Methods</h4>An observational cohort study (ClinicalTrials.gov identifier: NCT05548777) was conducted  ...[more]

Similar Datasets

| S-EPMC8143276 | biostudies-literature
| S-EPMC10273779 | biostudies-literature
| S-EPMC10284962 | biostudies-literature
| S-EPMC5568772 | biostudies-literature
| S-EPMC6699827 | biostudies-literature
| S-EPMC8898077 | biostudies-literature
| S-EPMC9925509 | biostudies-literature
| S-EPMC11432878 | biostudies-literature
| S-EPMC6913461 | biostudies-literature